Revolutionizing Therapies for Neurological Diseases

Healthy Ageing and Growing-up Healthy

SMDG is developing safe, innovative, disease-modifying and life-saving therapies for some of the most debilitating diseases our societies face today. SMDG's team has focused on neurodegenerative diseases and pediatric neurological disorders as the first diseases to tackle. We do this by utilizing our ground breaking and transformative platforms for targeted and safe delivery of therapies and genetic medicines and broad understanding of these diseases for designing first in-class therapeutics.

Developing 21st Century Medicines

Developing 21st century life-saving therapies requires bold vision and groundbreaking science. We utilize our proprietary and innovative therapeutic platforms to develop precision and targeted life-saving therapies.

Learn more about our science.

Learn more

To play, press and hold the enter key. To stop, release the enter key.

Inspired by Nature
Engineered to Heal

We are making
Tomorrow's Medicines

Precision Targeting and Receptor Mediated

We were inspired by nature to design and develop therapies for most debilitating diseases with no known or limited therapies.

We are a team of internationally renowned scientists who have been recognised globally for our work in drug delivery and research. We are innovators and entrepreneurs with extensive experience in studying nature of different diseases and designing innovative therapeutics utilising the latest technologies.

We have embarked on an ambitious path of designing better disease-modifying and First-in-Class therapies that could be safe for patients and are good for the environment.

Learn more about our science and platforms

News & Events

Dr. Farhangrazi invited to AI for Growth

Dr Shadi Farhangrazi is invited to attend UK-France, AI for Growth meeting in Paris

SMDG scientists among the top scientists in the world

SMDG scientists, Professor Moein Moghimi and Dr. Christy Hunter have been named to the List of World’s Most Cited researchers

Dr. Mark Treherne joins Science Advisory Board

Dr. Mark Treherne, a leading life science industry executive joins SMDG's Science Advisory Board.

Pioneering Research

Our chief scientist and inventor of our Peptide Therapeutic Platforms:

Professor Moein Moghimi's laboratory has been at the forefront of pioneering and innovative research in nanomedicine, drug delivery, and biomedical engineering. His team's groundbreaking work has led to the development of advanced nanoscale technologies for targeted drug delivery, immune modulation, and diagnostic applications. By exploring novel approaches to nanocarrier design, biocompatibility, and cellular interactions, Professor Moghimi’s research has significantly influenced the fields of nanopharmacology and precision medicine. His lab's discoveries continue to pave the way for safer and more effective therapeutic strategies, ultimately transforming patient care and advancing modern medicine.

Learn more about Professor Moghimi's research